Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer

宋国红; 邸立军; 邵　彬

doi:10.19401/j.cnki.1007-3639.2016.11.014

您当前的位置：

首页 >

文章列表页 >

Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer

更新时间：2025-12-31

- Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer
- China Oncology Vol. 26, Issue 11, Pages: 957-960(2016)
- 作者机构：
  
  北京大学肿瘤医院暨北京市肿瘤防治研究所，乳腺肿瘤内科，恶性肿瘤发病机制及转化研究教育部重点实验室,北京,100142
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2016.11.014
  CLC：
- Published Online：22 January 2017，
  
  Published：22 January 2016
- 稿件说明：
移动端阅览
宋国红,邸立军,邵　彬,等. 氟维司群500 mg治疗激素受体阳性复发转移性乳腺癌的疗效观察[J]. 中国癌症杂志, 2016, 26(11): 957-960.

宋国红, 邸立军, 邵　彬. Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer[J]. China Oncology, 2016, 26(11): 957-960.
宋国红,邸立军,邵　彬,等. 氟维司群500 mg治疗激素受体阳性复发转移性乳腺癌的疗效观察[J]. 中国癌症杂志, 2016, 26(11): 957-960. DOI： 10.19401/j.cnki.1007-3639.2016.11.014.

宋国红, 邸立军, 邵　彬. Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer[J]. China Oncology, 2016, 26(11): 957-960. DOI： 10.19401/j.cnki.1007-3639.2016.11.014.

摘要

Abstract

关键词

Keywords

references

Views

2426

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A retrospective study of 500 mg fulvestrant in recurrent or metastatic breast cancer patients pretreated with the third generation of aromatase inhibitors

Advances of fulvestrant in treatment of advanced breast cancer in hormone receptor-positive postmenopausal women

Related Author

赵燕南

龚成成

胡夕春

王佳玉

徐兵河

Related Institution

复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系

中国医学科学院肿瘤医院肿瘤内科

AI问答

⁰